Daunorubicin Clinical Trials
A listing of Daunorubicin medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 5 clinical trials
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug.
- 0 views
- 2 annotations
- 19 Feb, 2024
- 1 location
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by …
- 0 views
- 19 Feb, 2024
- 1 location
CPX-351 in Higher Risk Myelodysplastic Syndromes
Study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure
- 0 views
- 19 Feb, 2024
- 12 locations
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
There is currently lack of collaborative data on the epidemiology, clinicopathologic features and treatment outcome of newly diagnosed and relapsed APL in Asia. In addition, there is lack of data comparing oral- As2O3-based regimens with other treatment approaches, including intravenous As2O3,in the frontline or relapsed setting. With the long-term data …
- 0 views
- 19 Feb, 2024
- 1 location
Cancer Therapy Effects on the Heart
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death.
- 0 views
- 19 Feb, 2024
- 1 location